Myriad Genetics Company Profile (NASDAQ:MYGN)

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings results on Tuesday, May, 2nd. The company reported $0.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.24 by $0.03. The firm had revenue of $196.90 million for the quarter, compared to analyst estimates of $188.89 million. Myriad Genetics had a net margin of 4.26% and a return on equity of 10.53%. View Myriad Genetics' Earnings History.

Myriad Genetics issued an update on its fourth quarter earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $0.26-0.28 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26. The company issued revenue guidance of $192-194 million, compared to the consensus revenue estimate of $188.50 million.

13 brokerages have issued 1 year target prices for Myriad Genetics' shares. Their predictions range from $16.00 to $32.00. On average, they anticipate Myriad Genetics' stock price to reach $21.83 in the next year. View Analyst Ratings for Myriad Genetics.

Here are some recent quotes from research analysts about Myriad Genetics stock:

• 1. According to Zacks Investment Research, "Over the last three months, Myriad Genetics has been trading above the broader Medical - Biomedical and Genetics industry. The company saw strong growth in EndoPredict test revenues and sequential growth in hereditary cancer volumes in the last reported quarter. Recently, Myriad’s companion diagnostic program received a major boost in a new cancer indication, in collaboration with AstraZeneca. We are also optimistic in regard to Myriad’s collaboration with BeiGene for development of companion diagnostics. On the flip side, gross margin scenario is disappointing. Also the company’s narrowing bottom line guidance for fiscal 2017 is discouraging, indicating a looming concern ahead. Currency fluctuations and stiff competition are other major headwinds for the company." (7/17/2017)
• 2. Cowen and Company analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)
• 3. UBS AG analysts commented, "MYGN reported FY4Q16 earnings on Tuesday. Reported sales of $187m were roughly in-line with our estimate of $187m and consensus estimates of $188m. Adjusted EPS of $0.36 was below both our estimate of $0.38 and consensus estimates of $0.37. Most importantly, for FY2017, management guided to sales of $740m – $760m and adj. EPS of $1.00 – $1.10 compared to consensus forecasts of $790m and $1.77. We have lowered our FY2017 EPS forecast by 43%." (8/10/2016)

Some companies that are related to Myriad Genetics include Chemed Corp. (CHE), Sage Therapeutics (SAGE), Intercept Pharmaceuticals (ICPT), Cantel Medical Corp. (CMD), Juno Therapeutics (JUNO), Globus Medical (GMED), BeiGene (BGNE), INC Research Holdings (INCR), Ultragenyx Pharmaceutical (RARE), Insulet Corporation (PODD), LivaNova PLC (LIVN), GW Pharmaceuticals PLC (GWPH), Wright Medical Group N.V. (WMGI), The Medicines Company (MDCO), HealthEquity (HQY), China Biologic Products (CBPO), Hutchison China MediTech Limited (HCM) and Endo International PLC (ENDP).

Myriad Genetics' management team includes the folowing people:

• John T. Henderson M.D., Independent Chairman of the Board
• Mark C. Capone, President, Chief Executive Officer, Director
• Walter M. Gilbert Ph.D., Independent Vice Chairman of the Board
• R. Bryan Riggsbee CPA, Chief Financial Officer, Treasurer
• Virginia C. Drosos, President of Assurex Health, Inc.
• Alexander Ford, President of Myriad Genetic Laboratories, Inc.
• Ralph L. McDade Ph.D., President of Myriad RBM, Inc
• Bernard F. Tobin, President of Crescendo Bioscience, Inc
• Richard M. Marsh Esq., Executive Vice President, General Counsel, Secretary
• Gary A. King, Executive Vice President - International Operations

Myriad Genetics' stock is owned by many different of retail and institutional investors. Top institutional investors include CWM LLC (0.79%), Bank of Montreal Can (0.36%), BB&T Corp (0.31%), Adams Asset Advisors LLC (0.13%), Fisher Asset Management LLC (0.09%) and Eqis Capital Management Inc. (0.05%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh, S Louise Phanstiel and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Capstone Asset Management Co. and Creative Planning. View Insider Buying and Selling for Myriad Genetics.

Myriad Genetics' stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, BB&T Corp, State of Alaska Department of Revenue, Eqis Capital Management Inc., LeJeune Puetz Investment Counsel LLC, Aperio Group LLC and CWM LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Myriad Genetics stock can currently be purchased for approximately $24.16.